Pricing Log in Create free account

Tempest Therapeutics, Inc. (TPST) vs XTL Biopharmaceuticals Ltd. (XTLB)

Tempest Therapeutics, Inc. and XTL Biopharmaceuticals Ltd. are both Biotechnology companies. Tempest Therapeutics, Inc. and XTL Biopharmaceuticals Ltd. are of similar size ($7.5M and $7.3M). XTL Biopharmaceuticals Ltd. grew revenue faster over the last twelve months: −12.7% against −53.0%. Across the 11 metrics below, XTL Biopharmaceuticals Ltd. leads on 10 and Tempest Therapeutics, Inc. on 1.

Valuation

Metric TPST XTLB Biotechnology median
P/E n/m n/m 10.60
P/S 17.86 1.07 9.40
P/B n/m n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 22.37 0.99 9.02
Earnings yield (1,178.26%) (31.56%) (32.88%)
Free cash flow yield (365.85%) (176.08%) (23.13%)

Profitability

Metric TPST XTLB Biotechnology median
Gross margin 0.00% 0.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (931.14%) 0.00% (51.96%)
Return on assets (237.25%) 0.00% (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric TPST XTLB Biotechnology median
Revenue growth (TTM) (52.98%) (12.71%) 6.76%
EPS growth (last fiscal year) 67.55% (409.84%) 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric TPST XTLB Biotechnology median
Debt to equity 0.00 (1.83) 0.00
Current ratio 0.38 0.70 4.97
Net debt to EBITDA 0.29 (0.11) 1.01

Dividend

Metric TPST XTLB Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric TPST XTLB Biotechnology median
Market cap 7.50m 7.25m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack